Patient-reported outcomes (PROs) in patients with advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ?50% receiving cemiplimab (CEMI) monotherapy vs chemotherapy (CHEMO): EMPOWER-Lung 1 liver metastases subpopulation

Basit Öğe Kaydı
dc.contributor.authorBaramidze, A.
dc.contributor.authorGessner, C.
dc.contributor.authorGogishvili, M.
dc.contributor.authorSezer, A.
dc.contributor.authorMakharadze, T.
dc.contributor.authorKılıçkap, S.
dc.contributor.authorGümüş, M.
dc.date.accessioned2025-05-10T19:27:50Z
dc.date.issued2023
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstract[No abstract available]
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc.; Sanofi
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc. and Sanofi.
dc.identifier.endpageS71
dc.identifier.issn1556-0864
dc.identifier.issn1556-1380
dc.identifier.issue4
dc.identifier.scopusqualityQ1
dc.identifier.startpageS70
dc.identifier.urihttps://hdl.handle.net/20.500.14730/7077
dc.identifier.volume18
dc.identifier.wosWOS:000995007600050
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofJournal of Thoracic Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.titlePatient-reported outcomes (PROs) in patients with advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ?50% receiving cemiplimab (CEMI) monotherapy vs chemotherapy (CHEMO): EMPOWER-Lung 1 liver metastases subpopulation
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu